Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
10 participants
INTERVENTIONAL
2009-01-31
2011-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Magnesium Supplementation for Hypomagnesemia in Chronic Kidney Disease
NCT02216877
Parathyroid Hormone Levels in Relation to the Phosphorus Content of Meals
NCT00018135
Effect of Oral Magnesium on Vascular Calcification in Chronic Kidney Disease
NCT02542319
Magnesium Replacement and Hyperglycemia After Kidney Transplantation
NCT04382157
Initial Dosing of Paricalcitol in Secondary Hyperparathyroidism
NCT00307840
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
magnesium
magnesium 350 mg tablets once a day for 3 weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* treatment with calcium plus vitamin D analogue
* ionized calcium 1,0-1,29 mmol/L
* magnesium level 0,7-1,05 mmol/L
* TSH 0.1- 10 imU/L
Exclusion Criteria
* pregnancy
* creatinine \> 150 microM/L
* patient has used supplementary magnesium within 2 previous months
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Tartu
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Vallo Volke
Dr.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Vallo Volke, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Tartu, Institute of Physiology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tartu University Hospital
Tartu, , Estonia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UT296
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.